Literature DB >> 26553359

miR-198 targets SHMT1 to inhibit cell proliferation and enhance cell apoptosis in lung adenocarcinoma.

Shujun Wu1, Guojun Zhang2, Ping Li1, Shanshan Chen1, Furui Zhang1, Juan Li1, Chenyang Jiang3, Xiaonan Chen4, Yuanyuan Wang4, Yuwen Du4, Qianqian Sun4, Guoqiang Zhao5.   

Abstract

MiR-198 is involved in tumorigenesis, migration, invasion, and metastasis of various malignant cancers. However, the exact expression levels of miR-198 and the molecular mechanism underlying its role in lung adenocarcinoma require further exploration. In this study, quantitative real-time PCR was applied to study miR-198 and serine hydroxymethyltransferase 1 (SHMT1) expression in 47 paired lung adenocarcinoma tissues and adjacent nontumor lung tissues. Clinicopathological characters were analyzed. Pearson's correlation analysis was used to detect the relationship between miR-198 and SHMT1 expression. The function of miR-198 was explored by measuring cell proliferation, cell apoptosis, and the cell-cycle in vitro and in vivo. The target gene of miR-198 was certified using dual luciferase report assay. We found that in lung adenocarcinoma, miR-198 was significantly downregulated and SHMT1 was inversely upregulated. A strong negative correlation was noticed between miR-198 and SHMT1 expression. Further analysis revealed that miR-198 expression was associated with TNM stage and lymph node metastasis. Upregulated miR-198 could inhibit cell proliferation, enhance cell apoptosis, and lead to cell-cycle arrest in lung adenocarcinoma, which showed a more effective alteration than SHMT1 siRNA. Moreover, we identified SHMT1 as a target gene of miR-198. In conclusion, miR-198 suppressed proliferation of lung adenocarcinoma cells both in vitro and in vivo by directly targeting SHMT1. miR-198 may be a potential therapeutic target for lung adenocarcinoma in the near future.

Entities:  

Keywords:  Apoptosis; Lung adenocarcinoma; MiR-198; Proliferation; Serine hydroxymethyltransferase 1

Mesh:

Substances:

Year:  2015        PMID: 26553359     DOI: 10.1007/s13277-015-4369-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  27 in total

1.  Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification of lung adenocarcinoma.

Authors:  Zhen Chen; Xiaoyan Liu; Jing Zhao; Hanjin Yang; Xiaodong Teng
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

2.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

3.  Cancer statistics, 2015.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-01-05       Impact factor: 508.702

4.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

5.  Screening and in vitro testing of antifolate inhibitors of human cytosolic serine hydroxymethyltransferase.

Authors:  Alessandro Paiardini; Alessio Fiascarelli; Serena Rinaldo; Frederick Daidone; Giorgio Giardina; David R Koes; Alessia Parroni; Giulia Montini; Marina Marani; Alessio Paone; Lee A McDermott; Roberto Contestabile; Francesca Cutruzzolà
Journal:  ChemMedChem       Date:  2015-02-10       Impact factor: 3.466

6.  Livin expression may be regulated by miR-198 in human prostate cancer cell lines.

Authors:  Lin Ye; Sheng Li; Dingwei Ye; Deyong Yang; Feng Yue; Yanjie Guo; Xiaochi Chen; Feng Chen; Jianing Zhang; Xishuang Song
Journal:  Eur J Cancer       Date:  2012-10-13       Impact factor: 9.162

Review 7.  miRNAs in human cancer.

Authors:  Thalia A Farazi; Jessica I Spitzer; Pavel Morozov; Thomas Tuschl
Journal:  J Pathol       Date:  2010-11-18       Impact factor: 7.996

8.  MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma.

Authors:  Petra Vychytilova-Faltejskova; Igor Kiss; Sona Klusova; Jan Hlavsa; Vladimir Prochazka; Zdenek Kala; Jan Mazanec; Jitka Hausnerova; Leos Kren; Marketa Hermanova; Jiri Lenz; Petr Karasek; Rostislav Vyzula; Ondrej Slaby
Journal:  Diagn Pathol       Date:  2015-04-24       Impact factor: 2.644

Review 9.  Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line.

Authors:  Abdulaziz Al-Farsi; Peter Michael Ellis
Journal:  Front Oncol       Date:  2014-06-27       Impact factor: 6.244

10.  Site-specific metabolic phenotypes in metastatic breast cancer.

Authors:  Hye Min Kim; Woo Hee Jung; Ja Seung Koo
Journal:  J Transl Med       Date:  2014-12-14       Impact factor: 5.531

View more
  26 in total

1.  The moonlighting RNA-binding activity of cytosolic serine hydroxymethyltransferase contributes to control compartmentalization of serine metabolism.

Authors:  Giulia Guiducci; Alessio Paone; Angela Tramonti; Giorgio Giardina; Serena Rinaldo; Amani Bouzidi; Maria C Magnifico; Marina Marani; Javier A Menendez; Alessandro Fatica; Alberto Macone; Alexandros Armaos; Gian G Tartaglia; Roberto Contestabile; Alessandro Paiardini; Francesca Cutruzzolà
Journal:  Nucleic Acids Res       Date:  2019-05-07       Impact factor: 16.971

Review 2.  A potential role for estrogen in cigarette smoke-induced microRNA alterations and lung cancer.

Authors:  Amit Cohen; Mario Alberto Burgos-Aceves; Yoav Smith
Journal:  Transl Lung Cancer Res       Date:  2016-06

Review 3.  Reprogramming of serine, glycine and one-carbon metabolism in cancer.

Authors:  Albert M Li; Jiangbin Ye
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-05-19       Impact factor: 5.187

4.  Blocking the Metabolic Switch Toward Cytosolic 1C Flux: A Novel Therapeutic Approach for Tumors With Low SLC19A1 Expression.

Authors:  Zhe Chen; Hong Zhou; Haoliang Hu; Linxi Chen
Journal:  Pathol Oncol Res       Date:  2022-04-22       Impact factor: 2.874

5.  The promising role and prognostic value of miR-198 in human diseases.

Authors:  Xiaoping Wang; Yanxia Zhu; Qiuli Xie
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

6.  miR-198 inhibits the progression of renal cell carcinoma by targeting BIRC5.

Authors:  Chao Yuan; Zhenhong Su; Shengjie Liao; Duanzhuo Li; Zhiwen Zhou; Yawen Wang; Mingchun Quan; Lingling Zeng; Cai Lv; Chenyi Shen; Weida Gong; Jianfeng Wu; Xiaogang Chen; Wenbing Hu; Xu Lv; Wenxia Si; Xin Yu
Journal:  Cancer Cell Int       Date:  2021-07-21       Impact factor: 5.722

Review 7.  MicroRNAs and oncogenic transcriptional regulatory networks controlling metabolic reprogramming in cancers.

Authors:  Pannapa Pinweha; Khanti Rattanapornsompong; Varodom Charoensawan; Sarawut Jitrapakdee
Journal:  Comput Struct Biotechnol J       Date:  2016-06-04       Impact factor: 7.271

Review 8.  Exosomes as miRNA Carriers: Formation-Function-Future.

Authors:  Xiaojie Yu; Margarete Odenthal; Jochen W U Fries
Journal:  Int J Mol Sci       Date:  2016-12-02       Impact factor: 5.923

Review 9.  Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 Expression.

Authors:  Alessia Cimadamore; Silvia Gasparrini; Roberta Mazzucchelli; Andrea Doria; Liang Cheng; Antonio Lopez-Beltran; Matteo Santoni; Marina Scarpelli; Rodolfo Montironi
Journal:  Front Oncol       Date:  2017-12-12       Impact factor: 6.244

10.  Lower expressed miR-198 and its potential targets in hepatocellular carcinoma: a clinicopathological and in silico study.

Authors:  Wen-Ting Huang; Han-Lin Wang; Hong Yang; Fang-Hui Ren; Yi-Huan Luo; Chun-Qin Huang; Yue-Ya Liang; Hai-Wei Liang; Gang Chen; Yi-Wu Dang
Journal:  Onco Targets Ther       Date:  2016-08-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.